Innate Pharma SA announces that the preclinical rationale of the gamma-delta T cell immunotherapy in type-C viral hepatitis was presented today at the AASLD (American Association for the Study of Liver Diseases) Annual Meeting in San Francisco, USA.
| PR in english | 42.81 KB |
| CP en français | 45.2 KB |
| Poster_AASLD 08 | 625.62 KB |